Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
66980 studies found for:    "Pharmacologic Actions"
Show Display Options
Rank Status Study
1 Completed
Has Results
Prasugrel/Clopidogrel Maintenance Dose Washout Study
Condition: Coronary Artery Disease
Interventions: Drug: prasugrel;   Drug: clopidogrel
2 Completed A Study of MK-0893 on Glucagon-Induced Glycemic Excursion in Healthy Male Participants Following Intravenous Administration of Glucagon, Sandostatine® and Insulin (MK-0893-002)
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: MK-0893 10 mg;   Drug: MK-0893 40 mg;   Drug: MK-0893 200 mg;   Drug: MK-0893 1000 mg;   Drug: Placebo;   Biological: Sandostatine®;   Biological: Insulin;   Biological: Glucagon
3 Completed A Trial of Tadalafil and Glycemic Traits
Conditions: Cardiovascular Disease;   Insulin Resistance;   Glucose Intolerance;   Obesity
Interventions: Drug: Tadalafil;   Drug: Placebo
4 Completed Study of Safety, Tolerability, and Anti-Viral Effect of Locteron Compared to PEG-Intron in Patients With Chronic Hepatitis C
Condition: Hepatitis C
Interventions: Other: Locteron (controlled-release interferon alpha 2b);   Biological: pegylated IFNa2b
5 Recruiting Oral Testosterone for the Treatment of Hypogonadism in Males
Condition: Hypogonadism
Intervention: Drug: TSX-002
6 Terminated Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)
Conditions: Hepatocellular Carcinoma Non-resectable;   Hepatocellular Carcinoma Recurrent;   Carcinoma, Hepatocellular;   Liver Diseases;   Neoplasms by Histologic Type;   Digestive System Neoplasms;   Carcinoma;   Liver Neoplasms;   Neoplasms;   Neoplasms by Site;   Digestive System Diseases;   Adenocarcinoma;   Neoplasms, Glandular and Epithelial
Interventions: Drug: ABT-869;   Drug: Sorafenib
7 Completed Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal Cancer
Condition: Colorectal Cancer
Interventions: Biological: KRN330;   Drug: Irinotecan
8 Terminated Predictive Biomarkers of Response to Sunitinib in the Treatment of Poorly-differentiated NEURO-Endocrine Tumors
Conditions: Neuroendocrine Tumors;   Pancreatic Neoplasms;   Advanced Disease;   Sunitinib
Intervention: Drug: Sutent
9 Unknown  Levonorgestrel-Intrauterine System (LNG-IUS) Insertion in the Postpartum Period
Condition: Contraception
Intervention: Device: Levonorgestrel Intrauterine System (LNG-IUS: Mirena, Bayer)
10 Recruiting Antiplatelet Effects of Ticagrelor Versus Clopidogrel in American Indian Patients
Condition: Coronary Artery Disease
Interventions: Drug: Ticagrelor;   Drug: Clopidogrel
11 Completed Efficacy and Safety of Budesonide Foam for Patients With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis
Conditions: Proctitis;   Proctosigmoiditis
Interventions: Drug: Budesonide;   Drug: Placebo
12 Terminated Research Study of IV Vitamin C in Combination With Irinotecan vs Irinotecan Alone for Advanced Colorectal CA
Condition: Stage IV Colorectal Cancer
Intervention: Drug: Vitamin C
13 Recruiting The Effect of Uric Acid Lowering in Type 1 Diabetes
Condition: Type 1 Diabetes Mellitus
Intervention: Drug: Febuxostat
14 Completed
Has Results
Open-label, Single-arm Study to Assess the Pharmacokinetics, Safety, and Tolerability of a Single Subcutaneous Dose of Icatibant in Healthy Japanese Volunteers
Condition: Hereditary Angioedema (HAE)
Intervention: Drug: Icatibant (30 mg)
15 Recruiting Pharmacogenomics of Mood Stabilizer Response in Bipolar Disorder (PGBD)
Condition: Bipolar Affective Disorder
Intervention: Drug: Mood stabilizer treatment
16 Completed Ezetimibe In Addition To Atorvastatin Therapy On The Plaque Composition In Patients With Acute Myocardial Infarction.
Condition: ST-Segment Elevation Myocardial Infarction
Interventions: Drug: Ezetimibe;   Drug: Placebo
17 Active, not recruiting Safety and Efficacy of Oral LPCN 1021 in Men With Low Testosterone or Hypogonadism
Condition: Male Hypogonadism
Interventions: Drug: Oral testosterone undecanoate, LPCN 1021;   Drug: Topical testosterone gel 1.62 %
18 Completed Compare Ceftazidime-Avibactam and Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)
Conditions: cUTI;   Complicated Urinary Tract Infection;   Acute Pyelonephritis
Interventions: Drug: CAZ-AVI;   Drug: Doripenem;   Drug: Either switch to oral therapy : 500 mg of Ciprofloxacin (oral);   Drug: or switch to oral therapy : 800 mg/160 mg of sulfamethoxazole/trimethoprim
19 Recruiting Phase I Study of a Dendritic Cell Vaccine for Patients With Either Newly Diagnosed or Recurrent Glioblastoma
Conditions: Glioblastoma;   Glioblastoma Multiforme;   Glioma;   Astrocytoma;   Brain Tumor
Interventions: Biological: Dendritic cell vaccination, in addition to standard temozolomide chemotherapy and involved field radiation therapy;   Biological: Dendritic cell vaccination, with optional bevacizumab treatment for patients previously treated with bevacizumab
20 Suspended Daptomycin in Pediatric Patients With Bacterial Meningitis
Conditions: Meningitis;   Gram-Positive Bacteria
Intervention: Drug: Daptomycin

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years